

November 22, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval
for Acetazolamide Tablets”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary



Press Release

November 22, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval for Acetazolamide Tablets

Product to be launched immediately

Bangalore, November 22, 2017 Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval from the United States Food & Drug Administration (USFDA) for **Acetazolamide Tablets USP, 125 mg and 250 mg.**, a generic version of *Diamox Tablets®*.

According to IMS data, the US market for **Acetazolamide Tablets** is approximately USD 53 Million. The approval, which was received in a short span of 11 months, demonstrates company's strategy of building a niche portfolio in regulated markets, having limited competition.

The product, to be launched immediately, will be marketed by Strides Pharma Inc. in the US Market.


About Acetazolamide Tablets

Acetazolamide Tablets is used to prevent and reduce the symptoms of altitude sickness. Acetazolamide is also used with other medications to treat a certain type of eye problem (open-angle glaucoma).

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com



For further information, please contact:

<u>Strides:</u> Shashank Sinha, Managing Director +91 80 6784 0335 <u>Investors:</u> Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com	<u>PR Consultancy:</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.in K Priya: +91 95354 25418 priya@fortunapr.in
--	--

